Ten cancers had an upregulated CDKN2C expression, namely cholangiocarcinoma (CHOL), esophageal carcinoma (ESCA), glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSCC), kidney renal clear cell carcinoma (KIRC), LIHC, LUAD, lung squamous cell carcinoma (LUSC), stomach adenocarcinoma (STAD), and THCA (p < 0.05; Fig. 5A). This evidence concerns the gene CDKN2C and head and neck squamous cell carcinoma.